Ganciclovir ophthalmic

Drug Profile

Ganciclovir ophthalmic

Alternative Names: Ganciclovir ophthalmic gel 0.15%; ST-605; Virgan; Zirgan

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratoires Thea
  • Developer Laboratoires Thea; Ms Science; Sirion Therapeutics
  • Class Antineoplastics; Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ocular herpes simplex
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ocular herpes simplex
  • Phase II Cytomegalovirus infections

Most Recent Events

  • 31 Mar 2017 Ms Science Corporation completes a phase II trial for Cytomegalovirus infections (in patients with cytomegalovirus corneal endotheliitis) in Japan (Ophthalmic) (JapicCTI-163186)
  • 21 Jan 2016 Phase-II clinical trials in Cytomegalovirus infections in Japan (Ophthalmic) before January 2016 (Ms Science Corporation pipeline, January 2016)
  • 26 Apr 2010 Launched for Ocular herpes simplex (acute herpetic keratitis) in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top